Medicure Inc.

What they do

Medicure Inc. is a pharmaceutical company that develops and commercializes products for the cardiovascular market. Its operations include both proprietary and partnered products, with a focus on the U.S. and Canadian markets.

Revenue drivers

• Cardiovascular products — Primary revenue source from sales of its cardiovascular drug portfolio, including marketed products in the U.S. and Canada.
• U.S. sales — The U.S. is the largest market for its products, contributing the majority of revenue.
• Canadian sales — Canadian operations provide additional revenue, representing a smaller but stable market.

Recent performance

For the fiscal year ended December 31, 2025, the company reported financial results in Canadian dollars. The filing notes that at year-end, the exchange rate was US$1.00 = C$1.3706. Specific revenue and profit figures are not provided in the excerpts.

Strategy

Management's stated strategy focuses on growing its cardiovascular product portfolio in North America. The company continues to invest in research and development, patents, and licenses to support its pipeline. It also seeks to expand market share through existing product lines and potential partnerships.

Risks

• Currency risk — The company reports in Canadian dollars, so U.S. dollar fluctuations directly impact reported financials.
• Concentration risk — A significant portion of revenue depends on the U.S. market, making results sensitive to U.S. healthcare dynamics.
• Regulatory risk — As a pharmaceutical company, products are subject to FDA and Health Canada approvals, which can delay launches or limit market access.
• Competitive risk — The cardiovascular market is competitive, and generic or alternative therapies could reduce sales.

Outlook

Management is focused on advancing its product pipeline and expanding sales in both the U.S. and Canada. The company expects to continue investing in research and development to drive long-term growth.